NEW YORK (GenomeWeb News) – Complete Genomics said in a filing with the US Securities and Exchange Commission today that BGI-Shenzhen's tender offer to acquire the firm has been extended to midnight, New York City time, on Jan. 18.
The $118 million bid, which was launched in September, was scheduled to expire at midnight last Friday. Complete Genomics said that as of the close of business on Jan. 11, approximately 29.3 million shares representing around 83 percent of its outstanding common stock had been validly tendered and not withdrawn.
Complete Genomics also said in the SEC filing that the National Development and Reform Commission of the People's Republic of China had granted clearance of the proposed acquisition last Friday. The deal passed US Federal Trade Commission review last week.